Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric PatientsNovember 16th 2022
The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients with classical Hodgkin lymphoma.
Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC IndicationNovember 15th 2022
The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.
Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian CancerNovember 15th 2022
Mirvetuximab soravtansine-gynx, an antibody drug conjugate, has received accelerated approval for platinum-resistant ovarian cancer. The prescribing label comes with warnings for visual toxicities, pneumonitis, and peripheral neuropathy.
Distress in Advanced Cancer May Be Alleviated With Psychedelic-Assisted PsychotherapyNovember 15th 2022
Psychiatric distress and existential distress are associated with poor outcomes in patients with advanced cancers and treatment options such as psychotherapy have demonstrated limited effectiveness.
Real-World Study Demonstrates Benefits with Adjuvant Nivolumab in Resected Stage IIIA MelanomaNovember 14th 2022
A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab.
Rogaratinib May Be Effective for Patients With Bladder Cancer and FGFR3 DNA AlterationsNovember 14th 2022
Rogaratinib did not display a significant benefit over chemotherapy in patients with FGFR mutated bladder cancer, but the targeted treatment did generate encouraging responses among those with FGFR3 DNA alterations.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian CancerNovember 12th 2022
During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.
Oncology Drug Crash Course: Fam-Trastuzumab Deruxtecan-Nxki (Enhertu)November 8th 2022
After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.
Sylvester’s Sexual Health After Cancer Program Expands to Meet Needs of Women with CancerNovember 5th 2022
Kristin E. Rojas, M.D., FACS, FACOG, assistant professor of surgical oncology in the DeWitt Daughtry Department of Surgery and Sylvester Comprehensive Cancer Center at the University Miami Miller School of Medicine, realized she had struck a chord with women being treated for cancer when she started the Menopause Urogenital Sexual Health and Intimacy Clinic (MUSIC).
Sintilimab/Chemotherapy Regimen Boosts Progression-Free Survival in EGFR-Mutated NSCLCNovember 5th 2022
After 13.1 months of follow-up, the median progression-free survival in patients with EGFR-mutant non–small cell lung cancer who received a sintilimab-based regimen was 5.5 months.
Oncology Nurse Shares Top 5 Tips for Cancer CaregiversNovember 3rd 2022
For caregivers providing emotional and physical care for cancer patients, can be a positive, rewarding experience that brings people closer together. On the other hand, caring for someone in need also brings forth various challenges that can contribute to mental health concerns.
Adjuvant RCC Therapy Remains a Challenge as Treatment Landscape Continues to EvolveNovember 3rd 2022
Nancy Moldawer, RN, MSN, cochair of the Kidney Cancer Association's Clinical Advisory Board, speaks to unfolding data in the renal cell carcinoma space and the challenges in providing adjuvant therapy to this patient population.